where content, technology and people meet. (SM) Publishing and content technology executives use Shore to measure and understand their markets and competitors, define marketing strategies and implement successful content products and services using Shore's highly actionable insights into vendors, institutions, individuals and virtual communities.
ContentBlogger is the 2007 SIIA CODiE Award Winner for Best Media Blog
COMMENTARY:

Insights and headlines from Shore analysts on trends in enterprise and media content markets.
  Subscribe to our feed (?) or add to: MyYahoo  iGoogle/Google Reader  Bloglines  NewsGator  Rojo
Wednesday, November 17, 2004
This week the big news in the B2B segment was Dow Jones' bid to acquire MarketWatch. The online version of Dow Jones' pre-eminent publication, The Wall Street Journal, has been held up frequently as the exemplar of how the paid subscription model can work for certain established brands in the online news market. Now, Dow Jones appears to be acquiescing to the open access, ad-supported model to gain wider exposure and greater advertising dollars.

In the STM realm, publishers are faced with a similar trend toward open access for research articles that have historically been packaged into print journals for distribution. However, the response to the trend toward free access to previously premium content has been quite different in the STM environment. STM publishers like Reed Elsevier and Thomson are positioning themselves as providers of "solutions" to their constituent user groups in order to extract a premium. [Note, there is still an option for the open access content to be provided on an ad-supported basis.]

This week, Thomson Scientific announced Thomson Pharma, its new platform for accessing "premium patent, scientific, and financial content drawn from across the full range of Thomson-owned businesses". In its factsheet, Thomson Pharma is broadly described in three core elements:
Developing the complete pharmaceutical solution
Fuelling all stages of the drug development pipeline
Providing key functionality.

Overall, Thomson Pharma appears to be not much more than a collection of content with a specialized interface, but it is a step toward providing users with a "solution" that utilizes content to provide its answers--rather than a disconnected collection of content waiting to be sought out. Recent moves by Reed Elsevier also provide evidence of other STM publishing heavyweights' moving toward providing their content as part of an integrated package. Just last week, Reed Elsevier Ventures was the lead investor in a round of financing for Inpharmatica, a company that provides a drug discovery platform.

Professional publishing has always required knowledge of the target audience's business needs and applications. Now, more than ever, publishers of premium content need to move even closer to their ultimate users in order to provide services and solutions that merit premium prices.

By Janice - posted at 1:26 PM
permanent link to this entry        bookmark this entry:  AddThis Social Bookmark Tool
  0 comments (click to view or to add your own) 
Comments:  Post a Comment
 

To top of page To Top of Page

COMMENTARY: INDEX
CONTENTBLOGGER
INDUSTRY EVENTS
CONTENT NATION

Read ShoreLines, our free weekly email newsletter.

Sample issue
Follow us on Twitter
Get headline-only feed
Buzz news comments
RECENT ENTRIES
READ CONTENT NATION

Learn how to thrive and to survive as social media changes our work, our lives and our future.
Buy the book
Read it online
Read our social media blog
WEBLOGS: ARCHIVES
 
 

shorename.gif (1190 bytes)
[HOME] [US] [SERVICES] [COMMENTARY] [RESEARCH] [EVENTS] [PRESS] [CONTACT]
Copyright © 1997-2009 Shore Communications Inc.  All Rights Reserved - Click Here to Read Terms of Use
Corporate Privacy Policy

 

 

 

 

 

 

 

 This page is powered by Blogger. Isn't yours?